Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting.

British journal of haematology·2026
Same author

A Prospective Population-Based Study of Chimeric Antigen Receptor T-Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma.

Current oncology (Toronto, Ont.)·2026
Same author

Medication-related osteonecrosis of the jaw: incidence and risk factors in multiple myeloma patients undergoing pre-autologous stem cell transplant dental extractions.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026
Same author

Mel200 or BuMel conditioning in myeloma: is there a winner?

Blood·2025
Same author

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Related Experiment Video

Updated: Mar 6, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Current Review on High-Risk Multiple Myeloma.

Henry S H Chan1, Christine I Chen1, Donna E Reece2

  • 1Princess Margaret Cancer Centre, 610 University Ave, Toronto, ON, M5G 2M9, Canada.

Current Hematologic Malignancy Reports
|March 21, 2017
PubMed
Summary
This summary is machine-generated.

Recent advancements in multiple myeloma include new genetic risk factors and minimal residual disease detection. Novel combination therapies show promise for high-risk patients, improving outcomes.

Keywords:
High riskMultiple myelomaNovel agentsdel(17p)t(4;14)

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Related Experiment Videos

Last Updated: Mar 6, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Multiple myeloma risk stratification is evolving.
  • Genetics and minimal residual disease are key prognostic factors.

Purpose of the Study:

  • Provide an overview of recent changes in multiple myeloma risk stratification and treatment.
  • Summarize current data for clinical utility.

Main Methods:

  • Review of recent literature on multiple myeloma.
  • Synthesis of data on prognostic factors and therapies.

Main Results:

  • Disease genetics and minimal residual disease (MRD) are crucial prognostic indicators.
  • Combination therapies (proteasome inhibitors, immunomodulatory drugs) show efficacy in high-risk patients.
  • Emerging therapies target high-risk multiple myeloma.

Conclusions:

  • New risk stratification and treatment strategies are improving outcomes for multiple myeloma patients.
  • Understanding of high-risk disease has advanced significantly.
  • Ongoing research promises further therapeutic options.